167 related articles for article (PubMed ID: 21513851)
1. The relationship between MRI invasive features and expression of EMMPRIN, galectin-3, and microvessel density in pituitary adenoma.
Zhang Y; He N; Zhou J; Chen Y
Clin Imaging; 2011; 35(3):165-73. PubMed ID: 21513851
[TBL] [Abstract][Full Text] [Related]
2. CD147 expression in pituitary adenomas and its significance for clinical outcome.
Qu X; Yang W; Jiang M; Han T; Han L; Qu Y; Wang G; Shi D; Xu G
Hum Pathol; 2010 Aug; 41(8):1165-71. PubMed ID: 20381119
[TBL] [Abstract][Full Text] [Related]
3. Extracellular matrix metalloproteinase inducer expression in salivary gland tumors: a correlation with microvessel density.
Huang ZQ; Chen WL; Li HG; Li JS; Xu ZY; Lin ZY
J Craniofac Surg; 2010 Nov; 21(6):1855-60. PubMed ID: 21119439
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of magnetic resonance imaging criteria for cavernous sinus invasion in patients with pituitary adenomas: logistic regression analysis and correlation with surgical findings.
Vieira JO; Cukiert A; Liberman B
Surg Neurol; 2006 Feb; 65(2):130-5; discussion 135. PubMed ID: 16427401
[TBL] [Abstract][Full Text] [Related]
5. Immunohistochemical analysis of tumor angiogenic factors in human pituitary adenomas.
Niveiro M; Aranda FI; Peiró G; Alenda C; Picó A
Hum Pathol; 2005 Oct; 36(10):1090-5. PubMed ID: 16226108
[TBL] [Abstract][Full Text] [Related]
6. Clinicopathologic correlates of giant pituitary adenomas.
Chacko G; Chacko AG; Lombardero M; Mani S; Seshadri MS; Kovacs K; Scheithauer BW
J Clin Neurosci; 2009 May; 16(5):660-5. PubMed ID: 19285407
[TBL] [Abstract][Full Text] [Related]
7. Matrix metalloproteinase-2 expression correlates with cavernous sinus invasion in pituitary adenomas.
Liu W; Kunishio K; Matsumoto Y; Okada M; Nagao S
J Clin Neurosci; 2005 Sep; 12(7):791-4. PubMed ID: 16198918
[TBL] [Abstract][Full Text] [Related]
8. MR imaging of cavernous sinus involvement by pituitary adenomas.
Scotti G; Yu CY; Dillon WP; Norman D; Colombo N; Newton TH; De Groot J; Wilson CB
AJR Am J Roentgenol; 1988 Oct; 151(4):799-806. PubMed ID: 3262283
[TBL] [Abstract][Full Text] [Related]
9. Expression of survivin in invasive pituitary adenoma.
Zhang YC; Gao J; Xin T; Zheng ZM; Teng LZ
Saudi Med J; 2008 Nov; 29(11):1589-92. PubMed ID: 18998006
[TBL] [Abstract][Full Text] [Related]
10. [MRI diagnosis of sinus cavernous invasion by pituitary adenomas].
Moreau L; Cottier JP; Bertrand P; Destrieux C; Jan M; Sonier CB; Herbreteau D; Rouleau P
J Radiol; 1998 Mar; 79(3):241-6. PubMed ID: 9757244
[TBL] [Abstract][Full Text] [Related]
11. [Role of matrix metalloproteinases-9, 2 and their inhibitor-TIMP-1, 2 in invasive pituitary adenomas biological behavior].
He DS; Chen MZ; Wang HJ; Ke CL; Yan C; Zheng H; Hong YS
Ai Zheng; 2002 Oct; 21(10):1124-8. PubMed ID: 12508658
[TBL] [Abstract][Full Text] [Related]
12. Clinical tumor growth and comparison with proliferation markers in non-functioning (inactive) pituitary adenomas.
Saeger W; Lüdecke B; Lüdecke DK
Exp Clin Endocrinol Diabetes; 2008 Feb; 116(2):80-5. PubMed ID: 18072009
[TBL] [Abstract][Full Text] [Related]
13. Topoisomerase IIalpha expression in pituitary adenomas and carcinomas: relationship to tumor behavior.
Vidal S; Kovacs K; Horvath E; Rotondo F; Kuroki T; Lloyd RV; Scheithauer BW
Mod Pathol; 2002 Nov; 15(11):1205-12. PubMed ID: 12429800
[TBL] [Abstract][Full Text] [Related]
14. [Expression of pituitary tumor transforming gene, endostatin, and basic fibroblast growth factor mRNAs in invasive pituitary adenomas].
Chen L; Liu YS; Wang LS; Yin HG; Hou QT; Liu ZX; Chen LH; Ling F
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2004 Dec; 29(6):651-3, 666. PubMed ID: 16114549
[TBL] [Abstract][Full Text] [Related]
15. [Invasive giant pituitary adenomas].
Matsko DE; Vogel G; Ulitin AIu; Oliushin VE; Moes G; Pergamenshchikov AA; Burnin KS; Safarov BI; Markova NV
Arkh Patol; 2007; 69(2):46-50. PubMed ID: 17642195
[TBL] [Abstract][Full Text] [Related]
16. Galectin-3 expression in pituitary adenomas as a marker of aggressive behavior.
Righi A; Morandi L; Leonardi E; Farnedi A; Marucci G; Sisto A; Frank G; Faustini-Fustini M; Zoli M; Mazzatenta D; Agati R; Foschini MP
Hum Pathol; 2013 Nov; 44(11):2400-9. PubMed ID: 24007691
[TBL] [Abstract][Full Text] [Related]
17. Assessment of normal perisellar anatomy in 1.5 T T2-weighted MRI and comparison with the anatomic criteria defining cavernous sinus invasion of pituitary adenomas.
Knappe UJ; Jaursch-Hancke C; Schönmayr R; Lörcher U
Cent Eur Neurosurg; 2009 Aug; 70(3):130-6. PubMed ID: 19701871
[TBL] [Abstract][Full Text] [Related]
18. Expression and clinical significance of CD147 in genitourinary carcinomas.
Han ZD; He HC; Bi XC; Qin WJ; Dai QS; Zou J; Ye YK; Liang YX; Zeng GH; Zhu G; Chen ZN; Zhong WD
J Surg Res; 2010 May; 160(2):260-7. PubMed ID: 19286191
[TBL] [Abstract][Full Text] [Related]
19. Multiregional sampling reveals a homogenous distribution of Ki-67 proliferation rate in pituitary adenomas.
Wolfsberger S; Kitz K; Wunderer J; Czech T; Boecher-Schwarz HG; Hainfellner JA; Knosp E
Acta Neurochir (Wien); 2004 Dec; 146(12):1323-7; discussion 1327-8. PubMed ID: 15480830
[TBL] [Abstract][Full Text] [Related]
20. [Expression of galectin-3 in invasive prolactinomas].
Wang H; Wang MD; Ma WB; Yang D; Shi YF; Kong YG; Li SF; Li ZH; Wang RZ
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2005 Jun; 27(3):380-1. PubMed ID: 16038281
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
